Prostate cancer (PCa) is a worldwide issue, with a rapid increase in its occurrence and
mortality. Over the years, various strategies have been implemented to overcome the hurdles that exist
in the treatment of PCa. Consistently, there is a change in opinion about the methodologies in clinical
trial that have engrossed towards the treatment of PCa. Currently, there is a need to resolve these newly
recognized challenges by developing newer rational targeting systems. The ongoing clinical protocol
for the therapy using different targeting systems is undertaken followed by local targeting to cancer
site. A number of new drug targeting systems like liposomes, nanoemulsions, magnetic nanoparticles
(MNPs), solid lipid nanoparticles, drug-peptide conjugate systems, drug-antibody conjugate systems,
epigenetic and gene therapy approaches, and therapeutic aptamers are being developed to suit this protocol.
Recent advancements in the treatment of PCa with various nanocarriers have been reported with
respect to newly identified biological barriers and intended to solve the contexts. This review encompasses
the input of nanotechnology in particular targeting of PCa which might escape the lifethreatening
side effects and potentially contribute to bring fruitful clinical outcomes.